TX-FLUENCE
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the successful continuation of its partnership with Dutch organization Innexo BV (Innexo), a specialty agricultural contract research organization that focuses on molecular farming and medicinal plants.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201728532/en/
Fluence and Innexo's partnership tests the effects of eliminating the vegetation phase for cannabis cultivation. (Photo: Business Wire)
Fluence and Innexo’s research partnership is focused on assessing the viability of cultivating cannabis without a standard vegetative phase, a practice generally associated with lower energy use that passes savings directly to growers in Europe and around the globe. Preliminary data from Fluence and Innexo demonstrates the potential of the “no-veg” growing method to help growers save money while improving quality and consistency. The Fluence and Innexo teams intend to collaborate on a full-scale research project to validate these initial results.
“At Innexo, we use our deep knowledge of cannabis cultivars and best propagation practices to help growers create the most efficient cultivation strategies possible,” said Dominique van Gruisen, managing director of Innexo. “We naturally gravitate toward partners like Fluence who can match our expertise and commitment to investing in innovative and impactful cannabis research.”
Most commercial cannabis cultivators use a vegetative phase to ensure proper plant growth to support flower weight and to gain a full and dense canopy. This phase can last anywhere between seven days and four weeks, requiring a significant investment of time, electrical energy and resources. Initial findings from Fluence and Innexo demonstrate the potential of this method to maintain crop quality and yield while creating up to 55% savings on annual electrical costs directly associated with lighting.
When the plants would typically enter the vegetative phase, they were instead transplanted to the flowering room, where they immediately received their maximum light intensity. In this system, cannabis crops reach their final height—between 70 and 120 cm—around 28 days after transplant. Eliminating two weeks of vegetative phase represents up to 252 hours of direct electricity savings per light per crop cycle. Additional savings are realized through lower HVAC costs and generally more efficient cultivation cycles. Initial research indicates that “no-veg” growing is most effective with plant densities between eight and 10 plants per m2. Thus far, research has tested the viability of “no-veg” growing across six cannabis cultivars, 10 different nutrient lines and a wide range of light intensities.
“Proper lighting—which must include a strong combination of advanced fixtures and lighting strategy—plays a critical role in creating a more efficient and profitable methodology for cannabis cultivation,” said Dr. David Hawley, principal scientist at Fluence. “This research demonstrates the value of examining and investing in a research-backed lighting strategy from day one. Our goal is to explore, validate and demonstrate the effectiveness of diverse cultivation strategies to ensure every grower can apply data-driven methodologies to their facilities in collaboration with Fluence.”
Fluence and Innexo’s research uncovered potential savings for growers who pursue growing without a vegetative phase, including an average of both 40% lower electrical costs and up to 40% lower labor costs per crop cycle. Because of the fast-paced growth of the plants, researchers found there was less time for pests and diseases to develop, leading to a healthier end product. In addition, this method could reduce waste by eliminating C-Grade flower, which allows for more crop cycles per year and increases overall predictability for growers.
“At Fluence, we create value for growers throughout the world by investing in research that will expand the horizons of traditional cultivation,” said Sebastian Olschowski, research project manager for EMEA at Fluence. "As plant lighting specialists, we are proud to be part of this project to shape the future of cannabis research and transfer valuable knowledge to our customers and partners.”
Fluence and Innexo’s research collaboration, which began in 2022, has expanded to include collaborations in three of Innexo’s Acceleration Platform for Innovation (API) programs. API empowers innovative, small-scale companies adjacent to the cannabis industry to perform research in medical cannabis cultivation.
For more information on Fluence and its ongoing global research initiatives, visit www.fluence-led.com.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis, produce and flower markets, committed to enabling more efficient crop production for the world’s top greenhouse and indoor growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Professional Business. For more information about Fluence, visit www.fluence-led.com.
About Innexo BV
Innexo BV is a specialty agricultural contract research organization (CRO) based in the Netherlands. The focus and expertise of the company are in medicinal plants, such as cannabis and molecular farming in general. Innexo BV is part of the Botany Group of companies. To learn more about Innexo BV, visit www.innexo.nl.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201728532/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 21:46:00 CEST | Press release
Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to worki
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 18:09:00 CEST | Press release
Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom